As we are merging with the global service provider PharmaLex, our name has been changed to PharmaLex Finland.
The differences in the manufacturing process and the nature of the active substance itself mean that biologicals differ from traditional medicines in many ways.
The commission’s plan would not automatically apply an extended transitional period for all the medical devices, but the extension would be allowed on the condition that it is critical for the safety of the patients.
We are proud to introduce our new team of experts
With our Christmas donation, we support the activities of the John Nurminen Foundation to save the Baltic Sea and its heritage.
DRA Consulting has conducted an extensive preliminary report on the operating environment of the medicine supply chain, commissioned by the healthcare pool that operates under the National Emergency Supply Agency.
Company prepared the launch of vaccine in extremely tight timeline. They needed help to prepare linguistically and medically correct product information texts in extremely tight timeline.
Our Nordic Market Access team is growing, and we are looking for an additional team member to join us in Finland.
When a company reaches a certain size and a certain level of maturity, the investors and other industry operators start to show interest. That is what happened to us too.
DRA’s expert team grows even stronger. We are pleased to announce the addition of new top talents to our ranks.
When developing a new medicinal product, our client opted for a global approach: they wanted to access all the major markets, and to benefit from synergy, they decided to prepare the CMC documentation for the EU, FDA and Japan authorities simultaneously.
In celebration of DRA’s 20th anniversary, we can now offer a 20 % discount on the regular price of the trainings to our clients and partners.
DRA and PharmaLex are merging to create a centre of pharma and Health Tech expertise with nearly 3,000 experts. The merger will bring synergies for the customers of both companies while helping to accelerate Nordic cooperation in the pharmaceutical market.
PharmaLex expands Nordic footprint across key business units with DRA Consulting merger
In the global pharmaceutical market, the individual Nordic countries are very small. Together, they are much larger, but still relatively lightweight. This is certainly true if you look purely at sales volumes.
In this year’s ÄLY seminar organised by DRA, the discussion turned around different future visions about green pharmacy, corporate social responsibility, the latest innovations in health technology and the possibilities that quantum technology can offer for drug development.
The first web-based form to be released in the DADI project is a variations form for human medicinal products, and it is still expected to go live in October 2022.
Last year, we engaged all of our 100-plus employees in the organisation’s strategy work and visioning the future. This way, we managed to harness the silent knowledge of all our employees for the company’s foresight process, and by crowdsourcing, we also future-proofed our strategy.
Three guidance documents regarding in vitro diagnostic medical devices were published in May by the Medical Devices Coordination Group (MDCG).
DRA keeps growing! Warmly welcome Virve and Maura.
The Medical Device Coordination Group (MDCG) has provided guidance on how to better identify the borderline between a medical device and a drug.
In this blog post, our Health Tech Team Leader Tiina Riihimäki provides an overview of the latest developments and the foreseeable challenges in the process. Read her expert advice on how to prepare for this historic legislative change.
What does responsibility mean to you? What would you set as your goal for social responsibility in 2022? These are some of the questions that all DRA’s employees were asked in the beginning of this year.